U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07511023) titled 'Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum' on March 31.
Brief Summary: To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal cancer.
Study Start Date: Sept. 25, 2026
Study Type: INTERVENTIONAL
Condition:
Phase 2
Sacituzumab Tirumotecan
Refractory Metastatic
Unresectable Squamous
Cell Carcinoma of the Anus/ Rectum
Intervention:
DRUG: Sacituzumab Tirumotecan
Given by IV
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Ande...